Calla Lily Pioneers Treatment for Threatened Miscarriage with New Funding
Deal News | Apr 03, 2025 | Business Cloud
A team of scientists and biomedical engineers at Calla Lily Clinical Care have made a significant stride in medical technology by securing £1m in funding from the National Institute for Health and Care Research (NIHR). This funding will enable the development of an innovative device aimed at improving treatment for threatened miscarriage. The technology focuses on enhancing the efficacy and user experience of administering vaginal micronised progesterone, a treatment recommended for women experiencing bleeding during early pregnancy after a prior miscarriage. Currently, the challenge lies in medication leakage, leading to an economic burden on the NHS. The new device, Callavid, promises a hygienic and effective delivery method, potentially improving quality of life and reducing costs. Initial usability studies will begin shortly, with clinical trials following in 2025. This project aligns with NIHR's mission to support research that enhances health and well-being.
Sectors
- Healthcare
- Medical Devices
- Research and Development
Geography
- United Kingdom – The research, development, and funding activities described are taking place in the UK, where the National Institute for Health and Care Research operates.
Industry
- Healthcare – The article focuses on advancements in medical technology and funding related to improving healthcare treatments for threatened miscarriage.
- Medical Devices – The development and trial of the Callavid device for progesterone delivery directly pertains to the medical devices industry.
- Research and Development – The funding from NIHR and the planned clinical trials indicate significant activities in research and development within healthcare and MedTech.
Financials
- £1m – Funding awarded by NIHR for the development and clinical trial of Calla Lily Clinical Care's new device.
- £236m per year – Avoidable cost to the UK economy and NHS from ineffective progesterone administration.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Calla Lily Clinical Care | Target Company | Company | A team of scientists and biomedical engineers working on a new device to improve progesterone delivery for threatened miscarriage. |
| National Institute for Health and Care Research (NIHR) | Funder | Government | The UK agency providing £1m in funding to support health and social care research and innovation. |
| Dr. Lara Zibners | Co-founder and Chair | Person | Co-founder of Calla Lily Clinical Care, advocating for the technological advancement in treating threatened miscarriage. |
| Professor Michael Lewis | Scientific Director for Innovation | Person | Represents NIHR's perspective on funding and supporting Calla Lily Clinical Care's innovative project. |
| London School of Economics Care Policy and Evaluation Centre (CPEC) | Research Analyst | Company | Conducted an analysis highlighting the economic impact of current progesterone administration methods. |